Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab with irinotecan liposome in recurrent/metastatic nasopharyngeal carcinoma after anti-PD-(L)1 therapy
ChiCTR2500110090Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Sep 2025
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab and irinotecan liposome in nasopharyngeal carcinoma (NPC), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Overall response rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabirinotecan liposome
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2500110090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110090.